Wikipedia -WSS

Wikipedia

author：focus 2025-09-30 01:15:04 - browse：4974

Illustration of three connected puzzle pieces, with a woman standing near the missing/empty puzzle piece space. -- first opinion coverage from STAT — Adobe

Women have always been underrepresented in medical research. A new study reveals that not much has changed, especially when it comes to tests of cardiovascular devices.

In a paper published in JAMA Internal Medicine on Monday, researchers found that the percentage of women represented in high-risk medical device trials did not increase from 2010 to 2020. Women generally made up just 33% of participants when the team reviewed 195 trials published from 2016 to 2022. The percentages varied between devices: Women made up 46% of participants in orthopedic trials, but 29% in cardiovascular studies.

The issue isn’t new. The government has made some strides in correcting earlier missteps, like the Food and Drug Administration telling researchers in 1977 to exclude women of reproductive potential from early clinical trials. But stakeholders think agencies like the FDA could do more to incentivize the enrollment of women.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Why CTE doesn’t keep Americans from enjoying the Super Bowl

WSS

At ASCO, AstraZeneca reports strong data for breast cancer drug

A protest over insulin prices is seen as a fight for life

ASCO: AstraZeneca says CAR

BMI, flaws aside, is found to be useful estimate of body fat in youth

Gene therapy for Afghan refugees’ infant will be fully covered

The Biogen Aduhelm mess could happen again

explore

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Moonlake's readout produced a cash windfall. Risks remain

ASCO: AstraZeneca says CAR

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Hollywood unions extend contract negotiations for actors

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

The cancer drug shortage isn’t new — and neither are the solutions

Medicare Advantage plans can’t deny care with AI, CMS warns

Wildfire smoke exposes gaps in outdoor worker protections

How to increase colonoscopy rates? Looks like an AI can help

knowledge

How to increase colonoscopy rates? Looks like an AI can help

Updated Covid vaccine has 54% effectiveness, new study suggests

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Cano Health’s bankruptcy is a warning for Medicare Advantage

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Shifting the focus from loneliness to social health

focus

Wikipedia

leisure time

hotspot